Mounjaro and heart health: what the new US approval changes

Information verified on 6 September 2026. The US approvals cited do not prejudge the status in Morocco. This information sheet is not a substitute for medical advice.

The new US authorisation for Mounjaro concerns the prevention of cardiovascular events in adults with type 2 diabetes and high risk. It does not mean that anyone wishing to lose weight should be prescribed this medicine to ‘protect their heart’.

What was announced at the end of August 2026

On 28 August 2026, Lilly announced FDA approval of an indication for reducing the risk of major cardiovascular events – cardiovascular death, non-fatal heart attack or non-fatal stroke – in high-risk adults with type 2 diabetes. Mounjaro contains tirzepatide, which acts on GIP and GLP-1 receptors. Source: the manufacturer’s announcement regarding the US decision.

The country and the patient population are essential details. An expanded indication in the United States does not automatically change approvals in another country. In Morocco, the medicine’s authorisation status and prescribing conditions must be checked locally.

SURPASS-CVOT: a comparison with an active treatment

The trial compared tirzepatide with dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease. The comparator was therefore not a placebo, but a medicine already in use for its cardiovascular benefits. This distinction alters the interpretation. Source: SURPASS-CVOT publication.

A major event occurred in 12.2 per cent of participants on tirzepatide and 13.1 per cent on dulaglutide. The risk ratio was 0.92, with a confidence interval of 0.83 to 1.01. The trial demonstrated the non-inferiority specified in its protocol; it did not demonstrate statistical superiority on this primary endpoint.

‘Not inferior’ is not the same as ‘better’

A non-inferiority trial seeks to verify that one treatment is no less effective than another beyond a predefined margin. A superiority trial asks whether it performs better. These are two distinct questions, each with precise statistical rules.

The crude percentages above differ by 0.9 points. They describe the groups studied during the follow-up period and do not indicate a guaranteed benefit for any individual. Similarly, reading ‘8 per cent’ from the risk ratio does not mean that every patient will avoid eight events out of every hundred. Baseline risk, duration and uncertainty all play a part.

Who might find this information useful?

Cardiovascular protection remains a holistic strategy

A treatment decision takes into account blood glucose levels, blood pressure, lipid levels, smoking status, kidney function, medical history and tolerance. The fact that a medicine is new does not mean that other measures already prescribed are secondary. It simply adds an option to be discussed as part of a structured follow-up.

To make the most of your consultation, bring a list of the medicines you are taking, your latest available test results and any side effects you may have experienced. Ask what benefits are expected in your particular case, how these will be assessed and what alternatives are available.

This document provides an update on regulatory and scientific developments. It does not suggest any changes to treatment or advise on dosages. In the event of unusual chest pain, sudden shortness of breath or signs of a stroke, seek urgent medical assistance, regardless of the medication you are taking.

See also: GLP-1 tablets and How to interpret the results of retatrutide.

Original illustration generated by AI; it does not represent an identified commercial product or a real clinical situation.